Abstract:Background Mature aggressive B-cell lymphoma are heterogenous
malignancies that make up more than half of all diagnosed Non-Hodgkin
lymphoma in children and adolescents. The overall survival rate
increased over the last decades to 80–90%, due to fine tuning of
polychemotherapy. However, new therapeutic implications are needed to
further increase the overall survival. Current clinical trials analyze
the therapeutic effect of rituximab in pediatric patients, while the
mechanism of action in vivo is still not ful… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.